Latest News
Outsourcing in Clinical Trials UK & Ireland | June 14-15
24/05/2022
Are you attending the Outsourcing in Clinical Trials UK & Ireland meeting in London? This event will bring together attendees from both large and small established pharma alongside biopharmaceutical companies and provide opportunities to dive into the operational challenges and innovations in clinical development found within the UK & Ireland region. Simbec-Orion supports full service, […]
BIO International | June 13-16 | Meet Us in San Diego!
24/05/2022
We are excited to share that we will be attending BIO International in San Diego and are looking forward to re-connecting with our scientific colleagues in person. Our team would love to learn more about your clinical development goals and share how Simbec-Orion can support your team with flexible, thoughtful study design and deep scientific […]
American Society of Clinical Oncology Annual Meeting 2022
23/05/2022
The 2022 ASCO Annual Meeting Program will offer presentations on the latest research in cancer care. This year’s program will feature over 200 sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation. Our colleagues, Dr Moonmoon Kazi and Maria Frane are excited to be attending #ASCO2022 in Chicago next month and looking forward to […]
Simbec-Orion Modernizing Quality and Compliance with Veeva Vault Quality Suite
18/05/2022
Implementing Veeva Vault Quality Suite applications will help Simbec-Orion increase efficiency through digital execution, as well as strengthen QA processes, driving quality and oversight across our operations. Read the press release here. You might also be interested in reading our news about Alison Hughes, Head of Business Enablement at Simbec-Orion, being recognised as a Veeva […]
Lupuzor™ Phase III Trials: Partnering With Immupharma
03/02/2022
Lupuzor™ is an in-development treatment for Lupus, a chronic inflammatory disease thought to affect around 5 million people worldwide. Having recently undergone FDA approval, Lupuzor™ is commencing into phase 3 clinical trials. Simbec-Orion are proud to have been selected by ImmuPharma as a partner to conduct the international phase 3 trial of Lupuzor™ involving pharmacokinetic […]
Using biomarker clinical trial design to drive rare respiratory disease results
03/02/2022
Simbec-Orion recently helped a biotech sponsor demonstrate the safety and tolerability of a new trial treatment for idiopathic pulmonary fibrosis (IPF). Devising an effective umbrella trial design adapted to the needs of IPF patients, we were able to deliver final CSR results ahead of time. Our researchers devised and conducted the umbrella study design testing […]
Pulmonary Deposition of BUD/Glycopyrrolate/Formoterol in COPD Patients
18/10/2021
A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered dose inhaler in patients with moderate‑to‑very severe chronic obstructive pulmonary disease. Simbec-Orion worked with two leading organisations, Astra Zeneca and Cardiff Scintigraphics, to successfully complete a scintigraphy study in COPD patients. About the COPD study Study Title A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered […]
